Physician profile
Thomas Scott Baker
NPI 1104837327
$5,701.34
in general payments reported to CMS, 2019-2025
39 companies · $1,436 in 2025
The $1,436 reported for 2025 was more than what 79% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $587 · 2021: $610 · 2022: $657 · 2023: $837 · 2024: $793 · 2025: $1,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,065.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,000.03 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $870.91 | 2019-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $856.35 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies, General - Pain Management |
| Averitas Pharma INC. | $642.41 | 2023-2025 | Qutenza |
| Scilex Pharmaceuticals INC. | $321.22 | 2019-2025 | Ztlido |
| Protega Pharmaceutials INC | $298.34 | 2022-2025 | Roxybond |
| Pfizer INC. | $206.82 | 2019-2025 | |
| Abbvie INC. | $201.19 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Biodelivery Sciences International, INC. | $157.00 | 2019-2021 | |
| Amgen INC. | $113.83 | 2019-2022 | |
| Daiichi Sankyo INC. | $109.44 | 2019 | |
| Mdd US Operations, LLC | $92.59 | 2019-2020 | |
| Allergan, INC. | $84.37 | 2019-2021 | |
| Curonix LLC | $75.11 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbott Laboratories | $57.75 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sentynl Therapeutics, INC. | $49.76 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $49.61 | 2019-2020 | |
| Saluda Medical Americas, INC. | $44.07 | 2025 | Evoke |
| Pacira Therapeutics, INC. | $38.25 | 2020 | |
| Uswm, LLC | $37.64 | 2022 | |
| Hikma Pharmaceuticals USA | $37.53 | 2022 | |
| Almatica Pharma LLC | $35.71 | 2021 | |
| Nevro Corp. | $28.72 | 2019 | |
| Alnylam Pharmaceuticals INC. | $27.26 | 2024 | Givlaari |
| Tonix Medicines, INC. | $26.36 | 2025 | Tonmya |
| Axsome Therapeutics, INC. | $26.27 | 2025 | Symbravo |
| Ipsen Biopharmaceuticals, INC | $24.04 | 2024 | Dysport |
| Medtronic, INC. | $21.38 | 2024 | Intellis Adaptivestim |
| Azurity Pharmaceuticals, INC. | $20.95 | 2024 | Horizant |
| Depuy Synthes Sales INC. | $19.05 | 2024 | Monovisc, Orthovisc |
| Alexion Pharmaceuticals, INC. | $18.60 | 2024 | Strensiq |
| Lilly USA, LLC | $16.10 | 2022 | |
| Shionogi INC | $15.70 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $14.87 | 2019 | |
| Redhill Biopharma INC. | $14.04 | 2022 | |
| Eisai INC. | $12.82 | 2021 | |
| Radius Health, INC. | $12.37 | 2020 | |
| Horizon Therapeutics Plc | $11.97 | 2019 | |
| Zyla Life Sciences, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.